Public Health Fallout

A less likely but important risk is that FDA testing connects seized products to patient injuries or contaminated counterfeit ingredients. That would intensify scrutiny of online GLP-1 access and briefly weigh on companies exposed to obesity-drug branding and telehealth distribution.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.